Global Community-acquired Bacterial Pneumonia Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Page: 102

Published Date: 08 Jan 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

Community-acquired pneumonia (CAP) refers to pneumonia that is acquired in the community setting, which is caused by various bacterial species, such as S. pneumoniae, Haemophilus influenzae type b (Hib), Chlamydia pneumoniae, Mycoplasma, pneumoniae, or Legionella spp., and many others. Prevalence of pneumonia differs both regionally and by age group affecting from children to adults.

According to our (Global Info Research) latest study, the global Community-acquired Bacterial Pneumonia market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Community-acquired Bacterial Pneumonia market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Community-acquired Bacterial Pneumonia market size and forecasts, in consumption value ($ Million), 2018-2029
Global Community-acquired Bacterial Pneumonia market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Community-acquired Bacterial Pneumonia market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Community-acquired Bacterial Pneumonia market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Community-acquired Bacterial Pneumonia
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Community-acquired Bacterial Pneumonia market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Nabriva Therapeutics, Paratek Pharmaceuticals, Melinta Therapeutics, Allergan plc and Bayer AG, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Community-acquired Bacterial Pneumonia market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Pleuromutilin Antibiotic
    Cephalosporin
    Glycylcycline
    Oxazolidinone
    Ketolide
    Others

Market segment by Application
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

Market segment by players, this report covers
    Nabriva Therapeutics
    Paratek Pharmaceuticals
    Melinta Therapeutics
    Allergan plc
    Bayer AG
    Lupin Pharmaceuticals
    Mylan N.V.
    Sanofi S.A.
    Pfizer Inc.
    Dainippon Sumitomo Pharma
    Takeda Pharmaceutical Company Limited
    Basilea Pharmaceutica International AG

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Community-acquired Bacterial Pneumonia product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Community-acquired Bacterial Pneumonia, with revenue, gross margin and global market share of Community-acquired Bacterial Pneumonia from 2018 to 2023.
Chapter 3, the Community-acquired Bacterial Pneumonia competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Community-acquired Bacterial Pneumonia market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Community-acquired Bacterial Pneumonia.
Chapter 13, to describe Community-acquired Bacterial Pneumonia research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Community-acquired Bacterial Pneumonia
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Community-acquired Bacterial Pneumonia by Type
        1.3.1 Overview: Global Community-acquired Bacterial Pneumonia Market Size by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Global Community-acquired Bacterial Pneumonia Consumption Value Market Share by Type in 2022
        1.3.3 Pleuromutilin Antibiotic
        1.3.4 Cephalosporin
        1.3.5 Glycylcycline
        1.3.6 Oxazolidinone
        1.3.7 Ketolide
        1.3.8 Others
    1.4 Global Community-acquired Bacterial Pneumonia Market by Application
        1.4.1 Overview: Global Community-acquired Bacterial Pneumonia Market Size by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Hospital Pharmacies
        1.4.3 Retail Pharmacies
        1.4.4 Online Pharmacies
    1.5 Global Community-acquired Bacterial Pneumonia Market Size & Forecast
    1.6 Global Community-acquired Bacterial Pneumonia Market Size and Forecast by Region
        1.6.1 Global Community-acquired Bacterial Pneumonia Market Size by Region: 2018 VS 2022 VS 2029
        1.6.2 Global Community-acquired Bacterial Pneumonia Market Size by Region, (2018-2029)
        1.6.3 North America Community-acquired Bacterial Pneumonia Market Size and Prospect (2018-2029)
        1.6.4 Europe Community-acquired Bacterial Pneumonia Market Size and Prospect (2018-2029)
        1.6.5 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size and Prospect (2018-2029)
        1.6.6 South America Community-acquired Bacterial Pneumonia Market Size and Prospect (2018-2029)
        1.6.7 Middle East and Africa Community-acquired Bacterial Pneumonia Market Size and Prospect (2018-2029)

2 Company Profiles
    2.1 Nabriva Therapeutics
        2.1.1 Nabriva Therapeutics Details
        2.1.2 Nabriva Therapeutics Major Business
        2.1.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product and Solutions
        2.1.4 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Nabriva Therapeutics Recent Developments and Future Plans
    2.2 Paratek Pharmaceuticals
        2.2.1 Paratek Pharmaceuticals Details
        2.2.2 Paratek Pharmaceuticals Major Business
        2.2.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Solutions
        2.2.4 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Paratek Pharmaceuticals Recent Developments and Future Plans
    2.3 Melinta Therapeutics
        2.3.1 Melinta Therapeutics Details
        2.3.2 Melinta Therapeutics Major Business
        2.3.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Product and Solutions
        2.3.4 Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 Melinta Therapeutics Recent Developments and Future Plans
    2.4 Allergan plc
        2.4.1 Allergan plc Details
        2.4.2 Allergan plc Major Business
        2.4.3 Allergan plc Community-acquired Bacterial Pneumonia Product and Solutions
        2.4.4 Allergan plc Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 Allergan plc Recent Developments and Future Plans
    2.5 Bayer AG
        2.5.1 Bayer AG Details
        2.5.2 Bayer AG Major Business
        2.5.3 Bayer AG Community-acquired Bacterial Pneumonia Product and Solutions
        2.5.4 Bayer AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Bayer AG Recent Developments and Future Plans
    2.6 Lupin Pharmaceuticals
        2.6.1 Lupin Pharmaceuticals Details
        2.6.2 Lupin Pharmaceuticals Major Business
        2.6.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Solutions
        2.6.4 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 Lupin Pharmaceuticals Recent Developments and Future Plans
    2.7 Mylan N.V.
        2.7.1 Mylan N.V. Details
        2.7.2 Mylan N.V. Major Business
        2.7.3 Mylan N.V. Community-acquired Bacterial Pneumonia Product and Solutions
        2.7.4 Mylan N.V. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 Mylan N.V. Recent Developments and Future Plans
    2.8 Sanofi S.A.
        2.8.1 Sanofi S.A. Details
        2.8.2 Sanofi S.A. Major Business
        2.8.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Product and Solutions
        2.8.4 Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
        2.8.5 Sanofi S.A. Recent Developments and Future Plans
    2.9 Pfizer Inc.
        2.9.1 Pfizer Inc. Details
        2.9.2 Pfizer Inc. Major Business
        2.9.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Product and Solutions
        2.9.4 Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
        2.9.5 Pfizer Inc. Recent Developments and Future Plans
    2.10 Dainippon Sumitomo Pharma
        2.10.1 Dainippon Sumitomo Pharma Details
        2.10.2 Dainippon Sumitomo Pharma Major Business
        2.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product and Solutions
        2.10.4 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
        2.10.5 Dainippon Sumitomo Pharma Recent Developments and Future Plans
    2.11 Takeda Pharmaceutical Company Limited
        2.11.1 Takeda Pharmaceutical Company Limited Details
        2.11.2 Takeda Pharmaceutical Company Limited Major Business
        2.11.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product and Solutions
        2.11.4 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
        2.11.5 Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
    2.12 Basilea Pharmaceutica International AG
        2.12.1 Basilea Pharmaceutica International AG Details
        2.12.2 Basilea Pharmaceutica International AG Major Business
        2.12.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product and Solutions
        2.12.4 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
        2.12.5 Basilea Pharmaceutica International AG Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Community-acquired Bacterial Pneumonia Revenue and Share by Players (2018-2023)
    3.2 Market Share Analysis (2022)
        3.2.1 Market Share of Community-acquired Bacterial Pneumonia by Company Revenue
        3.2.2 Top 3 Community-acquired Bacterial Pneumonia Players Market Share in 2022
        3.2.3 Top 6 Community-acquired Bacterial Pneumonia Players Market Share in 2022
    3.3 Community-acquired Bacterial Pneumonia Market: Overall Company Footprint Analysis
        3.3.1 Community-acquired Bacterial Pneumonia Market: Region Footprint
        3.3.2 Community-acquired Bacterial Pneumonia Market: Company Product Type Footprint
        3.3.3 Community-acquired Bacterial Pneumonia Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Community-acquired Bacterial Pneumonia Consumption Value and Market Share by Type (2018-2023)
    4.2 Global Community-acquired Bacterial Pneumonia Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
    5.1 Global Community-acquired Bacterial Pneumonia Consumption Value Market Share by Application (2018-2023)
    5.2 Global Community-acquired Bacterial Pneumonia Market Forecast by Application (2024-2029)

6 North America
    6.1 North America Community-acquired Bacterial Pneumonia Consumption Value by Type (2018-2029)
    6.2 North America Community-acquired Bacterial Pneumonia Consumption Value by Application (2018-2029)
    6.3 North America Community-acquired Bacterial Pneumonia Market Size by Country
        6.3.1 North America Community-acquired Bacterial Pneumonia Consumption Value by Country (2018-2029)
        6.3.2 United States Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)
        6.3.3 Canada Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)
        6.3.4 Mexico Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)

7 Europe
    7.1 Europe Community-acquired Bacterial Pneumonia Consumption Value by Type (2018-2029)
    7.2 Europe Community-acquired Bacterial Pneumonia Consumption Value by Application (2018-2029)
    7.3 Europe Community-acquired Bacterial Pneumonia Market Size by Country
        7.3.1 Europe Community-acquired Bacterial Pneumonia Consumption Value by Country (2018-2029)
        7.3.2 Germany Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)
        7.3.3 France Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)
        7.3.4 United Kingdom Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)
        7.3.5 Russia Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)
        7.3.6 Italy Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)

8 Asia-Pacific
    8.1 Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Type (2018-2029)
    8.2 Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Application (2018-2029)
    8.3 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region
        8.3.1 Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Region (2018-2029)
        8.3.2 China Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)
        8.3.3 Japan Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)
        8.3.4 South Korea Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)
        8.3.5 India Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)
        8.3.6 Southeast Asia Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)
        8.3.7 Australia Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)

9 South America
    9.1 South America Community-acquired Bacterial Pneumonia Consumption Value by Type (2018-2029)
    9.2 South America Community-acquired Bacterial Pneumonia Consumption Value by Application (2018-2029)
    9.3 South America Community-acquired Bacterial Pneumonia Market Size by Country
        9.3.1 South America Community-acquired Bacterial Pneumonia Consumption Value by Country (2018-2029)
        9.3.2 Brazil Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)
        9.3.3 Argentina Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)

10 Middle East & Africa
    10.1 Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Type (2018-2029)
    10.2 Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Application (2018-2029)
    10.3 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country
        10.3.1 Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Country (2018-2029)
        10.3.2 Turkey Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)
        10.3.3 Saudi Arabia Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)
        10.3.4 UAE Community-acquired Bacterial Pneumonia Market Size and Forecast (2018-2029)

11 Market Dynamics
    11.1 Community-acquired Bacterial Pneumonia Market Drivers
    11.2 Community-acquired Bacterial Pneumonia Market Restraints
    11.3 Community-acquired Bacterial Pneumonia Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry
    11.5 Influence of COVID-19 and Russia-Ukraine War
        11.5.1 Influence of COVID-19
        11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
    12.1 Community-acquired Bacterial Pneumonia Industry Chain
    12.2 Community-acquired Bacterial Pneumonia Upstream Analysis
    12.3 Community-acquired Bacterial Pneumonia Midstream Analysis
    12.4 Community-acquired Bacterial Pneumonia Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Community-acquired Bacterial Pneumonia Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Community-acquired Bacterial Pneumonia Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Global Community-acquired Bacterial Pneumonia Consumption Value by Region (2018-2023) & (USD Million)
    Table 4. Global Community-acquired Bacterial Pneumonia Consumption Value by Region (2024-2029) & (USD Million)
    Table 5. Nabriva Therapeutics Company Information, Head Office, and Major Competitors
    Table 6. Nabriva Therapeutics Major Business
    Table 7. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product and Solutions
    Table 8. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 9. Nabriva Therapeutics Recent Developments and Future Plans
    Table 10. Paratek Pharmaceuticals Company Information, Head Office, and Major Competitors
    Table 11. Paratek Pharmaceuticals Major Business
    Table 12. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Solutions
    Table 13. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 14. Paratek Pharmaceuticals Recent Developments and Future Plans
    Table 15. Melinta Therapeutics Company Information, Head Office, and Major Competitors
    Table 16. Melinta Therapeutics Major Business
    Table 17. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product and Solutions
    Table 18. Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 19. Melinta Therapeutics Recent Developments and Future Plans
    Table 20. Allergan plc Company Information, Head Office, and Major Competitors
    Table 21. Allergan plc Major Business
    Table 22. Allergan plc Community-acquired Bacterial Pneumonia Product and Solutions
    Table 23. Allergan plc Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 24. Allergan plc Recent Developments and Future Plans
    Table 25. Bayer AG Company Information, Head Office, and Major Competitors
    Table 26. Bayer AG Major Business
    Table 27. Bayer AG Community-acquired Bacterial Pneumonia Product and Solutions
    Table 28. Bayer AG Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 29. Bayer AG Recent Developments and Future Plans
    Table 30. Lupin Pharmaceuticals Company Information, Head Office, and Major Competitors
    Table 31. Lupin Pharmaceuticals Major Business
    Table 32. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Solutions
    Table 33. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 34. Lupin Pharmaceuticals Recent Developments and Future Plans
    Table 35. Mylan N.V. Company Information, Head Office, and Major Competitors
    Table 36. Mylan N.V. Major Business
    Table 37. Mylan N.V. Community-acquired Bacterial Pneumonia Product and Solutions
    Table 38. Mylan N.V. Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 39. Mylan N.V. Recent Developments and Future Plans
    Table 40. Sanofi S.A. Company Information, Head Office, and Major Competitors
    Table 41. Sanofi S.A. Major Business
    Table 42. Sanofi S.A. Community-acquired Bacterial Pneumonia Product and Solutions
    Table 43. Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 44. Sanofi S.A. Recent Developments and Future Plans
    Table 45. Pfizer Inc. Company Information, Head Office, and Major Competitors
    Table 46. Pfizer Inc. Major Business
    Table 47. Pfizer Inc. Community-acquired Bacterial Pneumonia Product and Solutions
    Table 48. Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 49. Pfizer Inc. Recent Developments and Future Plans
    Table 50. Dainippon Sumitomo Pharma Company Information, Head Office, and Major Competitors
    Table 51. Dainippon Sumitomo Pharma Major Business
    Table 52. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product and Solutions
    Table 53. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 54. Dainippon Sumitomo Pharma Recent Developments and Future Plans
    Table 55. Takeda Pharmaceutical Company Limited Company Information, Head Office, and Major Competitors
    Table 56. Takeda Pharmaceutical Company Limited Major Business
    Table 57. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product and Solutions
    Table 58. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 59. Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
    Table 60. Basilea Pharmaceutica International AG Company Information, Head Office, and Major Competitors
    Table 61. Basilea Pharmaceutica International AG Major Business
    Table 62. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product and Solutions
    Table 63. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 64. Basilea Pharmaceutica International AG Recent Developments and Future Plans
    Table 65. Global Community-acquired Bacterial Pneumonia Revenue (USD Million) by Players (2018-2023)
    Table 66. Global Community-acquired Bacterial Pneumonia Revenue Share by Players (2018-2023)
    Table 67. Breakdown of Community-acquired Bacterial Pneumonia by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 68. Market Position of Players in Community-acquired Bacterial Pneumonia, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
    Table 69. Head Office of Key Community-acquired Bacterial Pneumonia Players
    Table 70. Community-acquired Bacterial Pneumonia Market: Company Product Type Footprint
    Table 71. Community-acquired Bacterial Pneumonia Market: Company Product Application Footprint
    Table 72. Community-acquired Bacterial Pneumonia New Market Entrants and Barriers to Market Entry
    Table 73. Community-acquired Bacterial Pneumonia Mergers, Acquisition, Agreements, and Collaborations
    Table 74. Global Community-acquired Bacterial Pneumonia Consumption Value (USD Million) by Type (2018-2023)
    Table 75. Global Community-acquired Bacterial Pneumonia Consumption Value Share by Type (2018-2023)
    Table 76. Global Community-acquired Bacterial Pneumonia Consumption Value Forecast by Type (2024-2029)
    Table 77. Global Community-acquired Bacterial Pneumonia Consumption Value by Application (2018-2023)
    Table 78. Global Community-acquired Bacterial Pneumonia Consumption Value Forecast by Application (2024-2029)
    Table 79. North America Community-acquired Bacterial Pneumonia Consumption Value by Type (2018-2023) & (USD Million)
    Table 80. North America Community-acquired Bacterial Pneumonia Consumption Value by Type (2024-2029) & (USD Million)
    Table 81. North America Community-acquired Bacterial Pneumonia Consumption Value by Application (2018-2023) & (USD Million)
    Table 82. North America Community-acquired Bacterial Pneumonia Consumption Value by Application (2024-2029) & (USD Million)
    Table 83. North America Community-acquired Bacterial Pneumonia Consumption Value by Country (2018-2023) & (USD Million)
    Table 84. North America Community-acquired Bacterial Pneumonia Consumption Value by Country (2024-2029) & (USD Million)
    Table 85. Europe Community-acquired Bacterial Pneumonia Consumption Value by Type (2018-2023) & (USD Million)
    Table 86. Europe Community-acquired Bacterial Pneumonia Consumption Value by Type (2024-2029) & (USD Million)
    Table 87. Europe Community-acquired Bacterial Pneumonia Consumption Value by Application (2018-2023) & (USD Million)
    Table 88. Europe Community-acquired Bacterial Pneumonia Consumption Value by Application (2024-2029) & (USD Million)
    Table 89. Europe Community-acquired Bacterial Pneumonia Consumption Value by Country (2018-2023) & (USD Million)
    Table 90. Europe Community-acquired Bacterial Pneumonia Consumption Value by Country (2024-2029) & (USD Million)
    Table 91. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Type (2018-2023) & (USD Million)
    Table 92. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Type (2024-2029) & (USD Million)
    Table 93. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Application (2018-2023) & (USD Million)
    Table 94. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Application (2024-2029) & (USD Million)
    Table 95. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Region (2018-2023) & (USD Million)
    Table 96. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Region (2024-2029) & (USD Million)
    Table 97. South America Community-acquired Bacterial Pneumonia Consumption Value by Type (2018-2023) & (USD Million)
    Table 98. South America Community-acquired Bacterial Pneumonia Consumption Value by Type (2024-2029) & (USD Million)
    Table 99. South America Community-acquired Bacterial Pneumonia Consumption Value by Application (2018-2023) & (USD Million)
    Table 100. South America Community-acquired Bacterial Pneumonia Consumption Value by Application (2024-2029) & (USD Million)
    Table 101. South America Community-acquired Bacterial Pneumonia Consumption Value by Country (2018-2023) & (USD Million)
    Table 102. South America Community-acquired Bacterial Pneumonia Consumption Value by Country (2024-2029) & (USD Million)
    Table 103. Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Type (2018-2023) & (USD Million)
    Table 104. Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Type (2024-2029) & (USD Million)
    Table 105. Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Application (2018-2023) & (USD Million)
    Table 106. Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Application (2024-2029) & (USD Million)
    Table 107. Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Country (2018-2023) & (USD Million)
    Table 108. Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Country (2024-2029) & (USD Million)
    Table 109. Community-acquired Bacterial Pneumonia Raw Material
    Table 110. Key Suppliers of Community-acquired Bacterial Pneumonia Raw Materials
List of Figures
    Figure 1. Community-acquired Bacterial Pneumonia Picture
    Figure 2. Global Community-acquired Bacterial Pneumonia Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Community-acquired Bacterial Pneumonia Consumption Value Market Share by Type in 2022
    Figure 4. Pleuromutilin Antibiotic
    Figure 5. Cephalosporin
    Figure 6. Glycylcycline
    Figure 7. Oxazolidinone
    Figure 8. Ketolide
    Figure 9. Others
    Figure 10. Global Community-acquired Bacterial Pneumonia Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 11. Community-acquired Bacterial Pneumonia Consumption Value Market Share by Application in 2022
    Figure 12. Hospital Pharmacies Picture
    Figure 13. Retail Pharmacies Picture
    Figure 14. Online Pharmacies Picture
    Figure 15. Global Community-acquired Bacterial Pneumonia Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 16. Global Community-acquired Bacterial Pneumonia Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 17. Global Market Community-acquired Bacterial Pneumonia Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
    Figure 18. Global Community-acquired Bacterial Pneumonia Consumption Value Market Share by Region (2018-2029)
    Figure 19. Global Community-acquired Bacterial Pneumonia Consumption Value Market Share by Region in 2022
    Figure 20. North America Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 21. Europe Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 22. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 23. South America Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 24. Middle East and Africa Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 25. Global Community-acquired Bacterial Pneumonia Revenue Share by Players in 2022
    Figure 26. Community-acquired Bacterial Pneumonia Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
    Figure 27. Global Top 3 Players Community-acquired Bacterial Pneumonia Market Share in 2022
    Figure 28. Global Top 6 Players Community-acquired Bacterial Pneumonia Market Share in 2022
    Figure 29. Global Community-acquired Bacterial Pneumonia Consumption Value Share by Type (2018-2023)
    Figure 30. Global Community-acquired Bacterial Pneumonia Market Share Forecast by Type (2024-2029)
    Figure 31. Global Community-acquired Bacterial Pneumonia Consumption Value Share by Application (2018-2023)
    Figure 32. Global Community-acquired Bacterial Pneumonia Market Share Forecast by Application (2024-2029)
    Figure 33. North America Community-acquired Bacterial Pneumonia Consumption Value Market Share by Type (2018-2029)
    Figure 34. North America Community-acquired Bacterial Pneumonia Consumption Value Market Share by Application (2018-2029)
    Figure 35. North America Community-acquired Bacterial Pneumonia Consumption Value Market Share by Country (2018-2029)
    Figure 36. United States Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 37. Canada Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 38. Mexico Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 39. Europe Community-acquired Bacterial Pneumonia Consumption Value Market Share by Type (2018-2029)
    Figure 40. Europe Community-acquired Bacterial Pneumonia Consumption Value Market Share by Application (2018-2029)
    Figure 41. Europe Community-acquired Bacterial Pneumonia Consumption Value Market Share by Country (2018-2029)
    Figure 42. Germany Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 43. France Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 44. United Kingdom Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 45. Russia Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 46. Italy Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 47. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value Market Share by Type (2018-2029)
    Figure 48. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value Market Share by Application (2018-2029)
    Figure 49. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value Market Share by Region (2018-2029)
    Figure 50. China Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 51. Japan Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 52. South Korea Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 53. India Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 54. Southeast Asia Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 55. Australia Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 56. South America Community-acquired Bacterial Pneumonia Consumption Value Market Share by Type (2018-2029)
    Figure 57. South America Community-acquired Bacterial Pneumonia Consumption Value Market Share by Application (2018-2029)
    Figure 58. South America Community-acquired Bacterial Pneumonia Consumption Value Market Share by Country (2018-2029)
    Figure 59. Brazil Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 60. Argentina Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 61. Middle East and Africa Community-acquired Bacterial Pneumonia Consumption Value Market Share by Type (2018-2029)
    Figure 62. Middle East and Africa Community-acquired Bacterial Pneumonia Consumption Value Market Share by Application (2018-2029)
    Figure 63. Middle East and Africa Community-acquired Bacterial Pneumonia Consumption Value Market Share by Country (2018-2029)
    Figure 64. Turkey Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 65. Saudi Arabia Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 66. UAE Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
    Figure 67. Community-acquired Bacterial Pneumonia Market Drivers
    Figure 68. Community-acquired Bacterial Pneumonia Market Restraints
    Figure 69. Community-acquired Bacterial Pneumonia Market Trends
    Figure 70. Porters Five Forces Analysis
    Figure 71. Manufacturing Cost Structure Analysis of Community-acquired Bacterial Pneumonia in 2022
    Figure 72. Manufacturing Process Analysis of Community-acquired Bacterial Pneumonia
    Figure 73. Community-acquired Bacterial Pneumonia Industrial Chain
    Figure 74. Methodology
    Figure 75. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Nabriva Therapeutics
Paratek Pharmaceuticals
Melinta Therapeutics
Allergan plc
Bayer AG
Lupin Pharmaceuticals
Mylan N.V.
Sanofi S.A.
Pfizer Inc.
Dainippon Sumitomo Pharma
Takeda Pharmaceutical Company Limited
Basilea Pharmaceutica International AG

Related Reports

Global Community-acquired Bacterial Pneumonia Supply, Demand and Key Producers, 2023-2029

Global Community-acquired Bacterial Pneumonia Supply, Demand and Key Producers, 2023-2029

date 20 Feb 2023

date Pharma & Healthcare

The global Community-acquired Bacterial Pneumonia market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Community-acquired Bacterial Pneumonia Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Community-acquired Bacterial Pneumonia Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 12 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Community-acquired Bacterial Pneumonia market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Global Community-acquired Bacterial Pneumonia Supply, Demand and Key Producers, 2024-2030

Global Community-acquired Bacterial Pneumonia Supply, Demand and Key Producers, 2024-2030

date 14 Feb 2024

date Pharma & Healthcare

The global Community-acquired Bacterial Pneumonia market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

Product Tags

Community-acquired Bacterial Pneumonia

Community Acquired Bacterial Pneumonia(CABP) Therapeutics

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>